Interferon Beta-1b Level in Parkinson’s Disease: Before and After SARS-CoV-2 Vaccination
International Clinical Neuroscience Journal,
Vol. 9 (2022),
10 January 2022
,
Page e23
Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disease. Immune response varies after vaccination in different patients. We aimed to evaluate interferon beta-1b (IFNβ-1b) level in patients with PD in response to inactivated SARS-CoV-2 (CoronaVac) vaccination.
Methods: Eight patients with the diagnosis of idiopathic PD and followed in the outpatient clinic (stages 1-2) were enrolled. Total blood count was performed before vaccination. IFNβ-1b levels were measured by ELISA and motor examination was performed before and two hours after vaccination.
Results: IFNβ-1b levels increased in three patients, whereas no change was detected in one patient and the levels decreased in four patients. Divergent responses were found related to the time of diagnosis.
Conclusion: The time of PD diagnosis, as well as the age of the patients, may be responsible for the variability of the post-vaccine immune response.
- Parkinson’s disease; Interferon beta-1b; COVID-19; Vaccination; Immune response; Inflammation; Cytokine.
How to Cite
References
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548-60. doi: 10.1001/jama.2019.22360.
Kouli A, Torsney KM, Kuan WL. Parkinson’s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane, AU: Codon Publications; 2018. doi: 10.15586/codonpublications.parkinsonsdisease.2018.ch1.
Tansey MG, Romero-Ramos M. Immune system responses in Parkinson’s disease: early and dynamic. Eur J Neurosci. 2019;49(3):364-83. doi: 10.1111/ejn.14290.
Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson’s disease. Acta Neuropathol. 2021;141(4):527-45. doi: 10.1007/ s00401-021-02268-5.
Chu K, Zhou X, Luo BY. Cytokine gene polymorphisms and Parkinson’s disease: a meta-analysis. Can J Neurol Sci. 2012;39(1):58-64. doi: 10.1017/s0317167100012695.
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42(9):781-5. doi: 10.1038/ng.642.
Rosen B, Kurtishi A, Vazquez-Jimenez GR, Møller SG. The intersection of Parkinson’s disease, viral infections, and COVID-19. Mol Neurobiol. 2021;58(9):4477-86. doi: 10.1007/s12035-021-02408-8 .
Ejlerskov P, Hultberg JG, Wang J, Carlsson R, Ambjørn M, Kuss M, et al. Lack of neuronal IFN-β-IFNAR causes Lewy body-and Parkinson’s disease-like dementia. Cell. 2015;163(2):324- 39. doi: 10.1016/j.cell.2015.08.069.
Nehammer C, Ejlerskov P, Gopal S, Handley A, Ng L, Moreira P, et al. Interferon-β-induced miR-1 alleviates toxic protein accumulation by controlling autophagy. Elife. 2019;8. doi: 10.7554/eLife.49930.
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75. doi: 10.1016/j.cytogfr.2020.06.001.
Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, et al. COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis. 2020;6:18. doi: 10.1038/s41531-020-00123-0.
Salman AA, Waheed MH, Ali-Abdulsahib AA, Atwan ZW. Low type I interferon response in COVID-19 patients: interferon response may be a potential treatment for COVID-19. Biomed Rep. 2021;14(5):43. doi: 10.3892/br.2021.1419.
Contoli M, Papi A, Tomassetti L, Rizzo P, Vieceli Dalla Sega F, Fortini F, et al. Blood interferon-α levels and severity, outcomes, and inflammatory profiles in hospitalized COVID-19 patients. Front Immunol. 2021;12:648004. doi: 10.3389/fimmu.2021.648004.
Azhideh A, Menbari-Oskouie I, Yousefi-Asl M. Neurological manifestation of COVID-19: a literature review. Int Clin Neurosci J. 2020;7(4):164-70. doi: 10.34172/icnj.2020.20.
Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalia LV, Alcalay R, Chiang HL, et al. COVID-19 vaccination for persons with Parkinson’s disease: light at the end of the tunnel? J Parkinsons Dis. 2021;11(1):3-8. doi: 10.3233/jpd-212573.
Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021;11(4):579. doi: 10.3390/ diagnostics11040579.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70. doi: 10.1002/mds.22340.
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.
Rivera A, Siracusa MC, Yap GS, Gause WC. Innate cell communication kick-starts pathogen-specific immunity. Nat Immunol. 2016;17(4):356-63. doi: 10.1038/ni.3375.
Walter MR. The role of structure in the biology of interferon signaling. Front Immunol. 2020;11:606489. doi: 10.3389/ fimmu.2020.606489.
Lang PA, Cervantes-Barragan L, Verschoor A, Navarini AA, Recher M, Pellegrini M, et al. Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. Blood. 2009;113(5):1045-52. doi: 10.1182/ blood-2007-10-117861.
Fox LE, Locke MC, Lenschow DJ. Context is key: delineating the unique functions of IFNα and IFNβ in disease. Front Immunol. 2020;11:606874. doi: 10.3389/fimmu.2020.606874.
Suran M. How prolonged isolation affects people with Parkinson disease during the COVID-19 Pandemic. JAMA. 2022;327(9):801-3. doi: 10.1001/jama.2022.1510.
Weyand CM, Goronzy JJ. Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc. 2016;13(Suppl 5):S422-S8. doi: 10.1513/AnnalsATS.201602- 095AW.
- Abstract Viewed: 98 times
- PDF Downloaded: 120 times